2 U.S. lawmakers have disclosed 4 Oramed Pharmaceuticals Inc. trades under the STOCK Act — 1 buy and 3 sells between 2021 and 2025. Congress has been net sellers of ORMP.
*Notional-weighted price return on lawmakers' disclosed buys of ORMP, marked to the latest close — per-share (share counts aren't disclosed).
| Date | Member | Type | Amount | Est. price | Latest close | Return |
|---|---|---|---|---|---|---|
| 2025-01-10 | Brad Knott | SELL | $15K–$50K | $2.39 | $4.38 2026-08-13 | -83.3% exit |
| 2022-01-14 | Andrew Garbarino | SELL | $1K–$15K | $11.05 | $4.38 2026-08-13 | +60.4% exit |
| 2021-10-01 | Andrew Garbarino | SELL | $1K–$15K | $20.93 | $4.38 2026-08-13 | +114.0% rt |
| 2021-04-23 | Andrew Garbarino | BUY | $1K–$15K | $9.78 | $4.38 2026-08-13 | -55.2% |
Return: buys marked to the latest close (open); sells tagged rt are realized round-trips vs a prior disclosed buy; exit = timing (stock move after the sale, seller's perspective).
2 members of the U.S. House and Senate have disclosed Oramed Pharmaceuticals Inc. transactions under the STOCK Act — 1 purchase and 3 sales. The full member-by-member breakdown, with dates and dollar ranges, is in the table above.
No member of Congress has disclosed a ORMP purchase in the last 90 days. STOCK Act filings lag the trade by up to 45 days, so newer buys may still be pending disclosure.
Every ORMP trade is marked to the latest close in the Return column; sells matched to a prior buy show a realized round-trip return.
Yes. Under the 2012 STOCK Act, members of Congress may buy and sell individual stocks but must publicly disclose each transaction within 45 days. Bargo surfaces those filings so you can see who traded ORMP and how it performed.